Collapse Subdiscussion
Autumn Brooke-Chelsea Matlock
Autumn Brooke-Chelsea Matlock
Feb 29, 2024Feb 29 at 7:52pm
Manage Discussion Entry
Trisha,
I agree, the patient in this scenario is having an anaphylactic reaction. Anaphylactic reactions can be either categorized as an immunoglobulin E response or a nonimmune response, however the treatment for these is empirically the same (Pflipsen and Colon, 2020). It is important that facilities that perform allergy immunotherapy are always aware of the emergent situations that can occur and be fully prepared if they occur.
Bernstein & Epstein (2022) discusses a prescreening process for patients to ensure high risk patients are not a candidate for allergy immunotherapy as well as creating a clinical staff that are educated regularly in recognizing signs and symptoms of anaphylaxis.
It seems like this patient presented in the scenario qualified for allergy immunotherapy through initial clinic screenings but will no longer be able to use this as a means to lessen their allergy management.
References:
Bernstein, D. I., & Epstein, T. G. (2022). Safety of Subcutaneous Allergen immunotherapy.
Allergy and Asthma Proceedings
,
43
(4), 267–271. https://doi.org/10.2500/aap.2022.43.220035
Pflipsen, M. C., & Colon, K. M. V. (2020). Anaphylaxis: recognition and management.
American Family Physician
,
102
(6), 355-362.
Reply
